COMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET
Company Participants
Steven Schultz - Senior Vice President-Investor Relations
Kabir Nath - Chief Executive Officer
Mike Falvey - Chief Financial Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Ritu Baral - Cowen
François Brisebois - Oppenheimer
Patrick Trucchio - H.C. Wainwright
Elemer Piros - EF Hutton Group
Neena Bitritto-Garg - Citi
Bert Hazlett - BTIG
Kyle Qian - CGS
Operator
Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference, Steven Schultz. You may begin.
Steven Schultz
Welcome all of you, and thank you for joining us today for our fourth quarter and year end 2022 results conference call. Again, my name is Steven Schultz. I’m the Senior Vice President of Investor Relations at COMPASS Pathways. And today, I'm joined by Kabir Nath, our Chief Executive Officer and Mike Falvey, our Chief Financial Officer. Dr. Guy Goodwin, our Chief Medical Officer is unable to join us today, so Kabir will be covering clinical development. The call is being recorded and will be available on the COMPASS Pathways Investor Relations website shortly after the conclusion of the call.
Before we begin, let me remind everyone that during the call today, the team will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. You should not place undue reliance on these forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements, as a result of various risks, uncertainties and other factors, including those risks and uncertainties described under the heading Risk Factors in our Annual Report on Form 10-K filed with the US Securities and Exchange Commission and in subsequent filings made by COMPASS with the SEC.
Additionally, these forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements, even if our estimates or assumptions change.
With that, I'll now hand the call over to Kabir Nath.
Kabir Nath
Thank you, Steve. Good day everyone, and thank you for joining us. We have quite a bit to share with you, as we continue to make strong progress across all aspects of our business. During this past quarter, we started our COMP360 Phase III pivotal program in treatment-resistant depression or TRD, a unique achievement, the first ever Phase III trial of psilocybin.